EyeGene Inc.

EyeGene Inc.
Stock Exchange Korea Exchange
EPS
KRW856
Market Cap
KRW261.64 B
Shares Outstanding
10.99 M
Public Float
9.41 M

Profile

Address
Unit 910, Gangseo Han-gang Zai B
Seoul SL 07528
Korea, Republic Of
Employees -
Website http://www.eyegene.co.kr
Updated 09/14/2018
Eyegene, Inc. engages in the research and development of pharmaceutical products. Its products include curing technologies and vaccines for diabetic retinopathy, decubitus ulcer, cervical cancer, and adjuvant immunotherapy. The company was founded on June 23, 2000 and is headquartered in Seoul, South Korea.

Financials

View All
Created with Highcharts 5.0.14EyeGene Inc.Net Income. Fiscal year is January-December. All values KRW Thousands.3 854 8583 854 8582 925 8352 925 8354 897 0914 897 0918 269 8388 269 8388 450 8908 450 8902013201420152016201702M4M6M8M10M
Created with Highcharts 5.0.14EyeGene Inc.Sales/Revenue. Fiscal year is January-December. All values KRW Thousands.186 189186 189153 793153 793107 562107 562267 234267 234301 033301 03320132014201520162017050k100k150k200k250k300k350k

Won-Il Yoo
Chief Executive Officer & Director
Yang-Je Cho
Chief Technology Officer & Director